1. Equimolar amounts of y-~-glutamyl-~3,4-dihydrox yphen ylalanine (gludopa) and y-L-glutam yl-5-hydroxy-~-tryptophan were infused separately and together in eight healthy, salt-replete male subjects in a placebo-controlled, cross-over study to investigate whether the administration of one amine precursor affects the renal metabolism of the other and to determine whether dopamine or 5-hydroxytryptamine would be generated preferentially. The overall effect on sodium excretion was also measured when both precursors were administered simultaneously. 2. Administration of gludopa was associated with marked increases in the urinary excretion of L-dopa, dopamine and 3,4-dihydroxyphenylacetic acid, together with a rise in the urinary excretion of sodium. y-~-Glutamyl-5-hydroxy-~-tryptophan, on the other hand, produced marked increases in the urinary excretion of 5-hydroxy-~-tryptophan, 5-hydroxytryptamine and 5-hydroxyindoleacetic acid, and this was accompanied by a slight, but non-significant, reduction in sodium excretion. About 27% of the infused dose of gludopa (on a molar basis) was recovered in the urine as dopamine whereas 15% of the given dose of y-~-glutamyl-5-hydroxy-~-tryptophan was excreted as 5-hydroxytryptamine. 3. The urinary excretion values of L-dopa, dopamine and 3,4-dihydroxyphenylacetic acid after the simultaneous infusion of gludopa and y-~-glutamyl-5-hydroxy-L-tryptophan were not significantly different from those observed after infusion of gludopa only. Similarly, the urinary excretion values of 5-hydroxy-L-tryptophan, 5-hydroxytryptamine and 5-hydroxyindoleacetic acid during the co-infusion were similar to those measured after administration of y-Lglutamyl-5-hydroxy-~-tryptophan only. The net effect of the concomitant infusion of both glutamyl derivatives was an increase in urinary sodium excretion. 4. Our study in salt-replete individuals suggests that dopamine rather than 5-hydroxytryptamine was preferentially produced when equimolar amounts of their precursors were provided and that the natriuretic effect of dopamine, generated intrarenally from gludopa, was greater than the sodium retaining action of 5-hydroxytryptamine derived from y-~-glutamyl-5-hydroxy-L-tryptophan. Comparison of the urinary metabolite data after the separate and concomitant infusion of the two glutamyl compounds provided no evidence of competitive inhibition of synthesis of either amine.
INTRODUCTION
The same enzyme, aromatic L-amino acid decarboxylase (LAAD; EC 4.1.1.28), catalyses the decarboxylation of L-dopa (~-3,4-dihydroxyphenylalanine) and 5-hydroxy-~-tryptophan ( L -~H T P ) to produce dopamine (3,4-dihydroxyphenylethylamine) and 5-hydroxytryptamine (5-HT; serotonin) respectively [ 11. These biogenic amines are both primarily metabolized by monoamine oxidase (MAO; EC 1.4.3.4). 5-HT is converted by MAO-A to produce 5-hydroxyindoleacetaldehyde which is promptly degraded to 5-hydroxyindoleacetic acid (5-HIAA), the major excretory product of 5-HT metabolism. Dopamine, on the other hand, is readily metabolized by both MAO-A and MAO-B to form 3,4-dihydroxyphenylacetic acid (DOPAC). Both LAAD and MA0 are present in high concentrations in the mammalian kidney and there is evidence that dopamine [2] and 5-HT [3-61 can be synthesized intrarenally from their immediate precursors. Increased renal dopamine production is associated with a natriuresis whereas enhanced 5-HT synthesis is accompanied by a reduction in urinary sodium output. Thus, dopamine and 5-HT share common synthetic and metabolic pathways but have opposite effects on sodium excretion. It is possible that these amines may be generated within the kidney as reciprocal regulatory paracrine substances in the local control of sodium excretion, and more, or less, proposition is supported by the observations that a reduction in 5-HT synthesis [7] and an increase in dopamine excretion [8-1 11 occur with salt loading, whereas a low sodium diet results in decreased urinary excretion of dopamine [12] and an increase in the renal production of 5-HT in man [7] .
The kidney is highly active in the uptake and metabolism of y-glutamyl derivatives of amino acids and peptides [13, 141 due to the high activity of yglutamyltransferase (y-GT; EC 2.3.2.2) in the renal tissues, particularly in the proximal tubules Cl5, 161. These observations suggest that the y-glutamyl group may provide a convenient carrier for directing compounds containing an amino group into kidney metabolism, resulting in relative renal selectivity and absence of systemic effects. We have applied this y-glutamyl prodrug approach to enhance the delivery of L-dopa and L -~-H T P to the kidney in man and demonstrated that administration of y-~-glutamyl-~-3,4-dihydroxyphenylalanine (gludopa) and y-~-glutamyl-5-hydroxy-~-tryptophan (glu-5-HTP), the y-glutamyl derivatives of L-dopa and L-~-HTP, leads to marked increases in the renal synthesis of dopamine and 5-HT respectively [5, 171. Renal y-GT catalyses the cleavage of the yglutamyl linkage of these compounds. The resulting L-dopa and L -~-H T P are then decarboxylated to dopamine and 5-HT respectively by LAAD which is also present in high concentrations in the proximal tubules of the kidney [l, 18, 191. In the present study, we have infused equimolar doses of these relatively selective renal dopamine and 5-HT precursors separately and together in salt-replete healthy male subjects to investigate whether the administration of one amine precursor affects the metabolism of the other amine given that similar enzymes are involved in the synthesis and degradation of dopamine and 5-HT. We were also interested in determining whether dopamine or 5-HT is preferentially generated and the overall effect on sodium excretion.
METHODS
Eight male subjects, aged 19-37 years (mean 27.9 years) and weighing 54.4-86.2 kg (mean 70.3 kg), were recruited to this randomized, single-blind, placebo-controlled, within-subject cross-over study. They were in good health as judged by medical history, physical examination, ECG, urinalysis, full blood count, serum electrolytes, creatinine and liver function tests. They were on no medication for at least 2 weeks before the start of the study and until its completion. The study was approved by the Lothian Research Ethics Committee, and written informed consent was obtained from all participants.
The subjects were each studied on four separate occasions, separated by at least 10 days. They had been given dietary advice to refrain from salty and highly processed food and to avoid adding salt to their food over the 3 days before each study day. During that period, they took five tablets of Slow Sodium (Ciba Laboratories, Horsham, U.K.) four times daily at 08.00, 12.00, 16.00 and 20.00 hours, giving a total of 200mmol additional sodium intake per day. These measures were taken in an attempt to ensure that the subjects were salt-replete (or saltloaded) and to reduce the variability in dietary sodium intake between the study days. The subjects refrained from alcohol for 24h, abstained from xanthine-containing drinks from 18.00 hours, and fasted from 22.00 hours the evening before each study day. They collected their urine during the 24 h period before each experimental day to allow an assessment of their daily sodium intake.
They arrived at the clinical investigation unit at about 08.00 hours having drunk 500ml of tap water 1 h previously. An intravenous cannula was inserted into each forearm, one for administration of infusions and the other in the contralateral arm for blood sampling. The subjects received loading doses of 0.5g of p-aminohippurate sodium (PAH; Merck Sharp and Dohme, PA, U.S.A.) and 3.5g of polyfructosan (Inutest; Laevosan-Gesellschaft, Linz, Austria) intravenously at the start of the study (time = 0 h), followed by a maintenance infusion of PAH (3.75g/l) and polyfructosan (4.5g/l) in 0.9% sodium chloride (saline; 150mmol/l) at a constant rate of 5ml/min for the next 6 h to allow estimation of effective renal plasma flow (ERPF) and glomerular filtration rate (GFR). After a 3 h run-in period, they received placebo or gludopa from one infusion pump and placebo or glu-5-HTP from another pump intravenously into the same arm. Equimolar amounts (54.4 nmol min-' kg-') of gludopa (18.7 pg min-lkg-l) and glu-5-HTP (20pgmin-'kg-') were given over 1 h. Each solution was made up to a total volume of 30ml with saline and infused at 0.5ml/min. Placebo was 30ml of saline alone. Each subject therefore received the following four combinations in a randomized order: placebo and placebo; gludopa and placebo; placebo and glu-5-HTP; gludopa and glu-5-HTP. Accurately timed consecutive urine collections of about 30 min duration were started half an hour before the infusion of the test compounds and continued until 2 h after their completion. In addition to the saline administered intravenously, the subjects drank 200ml of water every half hour to promote an adequate urine flow. They remained semi-recumbent or supine throughout the experiment, except when standing up to micturate.
The volume of each urine collection was recorded and aliquots stored at -40°C for analysis of sodium, PAH, polyfructosan, L-dopa, dopamine, DOPAC, L-~-HTP, 5-HT and 5-HIAA. Urine samples for dopamine, DOPAC, 5-HT and 5-HIAA were acidified (pH <3.0) with 5mol/l HCl to prevent their oxidation. Venous blood samples were collected into lithium heparin tubes at 30 min intervals for measurement of plasma sodium, PAH and polyfructosan. Plasma was separated after centrifugation at 4°C and stored at -40°C until analysis.
Sodium was measured by an ion-selective electrode analyser (Radiometer KNA1, Crawley, West Sussex, U.K.). PAH, L-dopa, dopamine, DOPAC, L-5-HTP and 5-HT were measured by HPLC, and polyfructosan and 5-HIAA by spectrophotometry. These methods have been described previously [5,
Gludopa and glu-5-HTP were supplied by Aalto Bio Reagents Ltd, Dublin, Ireland. Both preparations contained 95% pure peptide. They were prepared for use in 0.9% saline by the Edinburgh Royal Infirmary Pharmacy and stored in vials at 201.
-40°C.
Calculations and statistical analysis
Renal clearance was calculated using the standard formula U V P , where U is the urine concentration, Vis the urine flow rate and P is the mean of the plasma levels at the beginning and end of each clearance period. ERPF and GFR were estimated by calculating the renal clearances of PAH (CPAH) and polyfructosan (CJ respectively, and the values were corrected to a body surface area of 1.73m2. The filtration fraction (FF) was calculated as (C,JCpAH) x 100%. Fractional excretion of sodium (FE,,) was calculated as renal clearance of sodium divided by GFR (C,J and expressed as a percentage.
All results are expressed as means f SD. Variables measured serially on the four experimental days were compared by repeated measures analysis of variance, with the different treatment (infusion) regimens and time as the within-subject repeated measures. The cumulative data between the four treatment regimens were compared using two-way analysis of variance, followed by Student's t-test for paired observations to determine where the differences lie if analysis of variance revealed a significant overall difference. The changes in 3-6 h cumulative sodium and urine output, relative to baseline excretion rates, were calculated and used in the analysis rather than the absolute 3-6 h cumulative values, to take into account the differences in baseline excretion rates between study days. The P values were adjusted by the Bonferroni method to allow for multiple comparisons and to protect against a type 1 error, and the associated 99%, rather than 95%, confidence interval of the difference between the means (CIdiff) is quoted where appropriate. Values of P c 0.05 were considered statistically significant. SPSS/PC + 5.0 statistical software package (SPSS Inc, Chicago, IL, U.S.A.) was employed for statistical analyses. Table 1 shows the urinary excretion rates all of dopamine, L-dopa and DOPAC for each 30min period before, during and after administration of the four infusion regimens. Urinary dopamine excretion remained relatively constant during infusion of saline on the placebo day. The administration of gludopa produced a marked increase in the rate of dopamine excretion from a baseline value of 1.6 nmol/min during the preinfusion clearance period (2.5-3.Oh) to a peak value of 622nmol/min during the collection period (3.5-4.0 h) at the end of the infusion. The 3-6 h cumulative dopamine excretion after gludopa was 215-fold higher than that after placebo infusion only ( Table 2 ). This increase in urinary dopamine excretion represented 27 f 7% of the infused dose of gludopa (on a molar basis) ( Table 3 ). Administration of gludopa also produced marked increases in the urinary excretion rates of Ldopa and DOPAC. At the end of the study period, 54+ 11% of infused gludopa was recovered in the urine as the sum of L-dopa, dopamine and DOPAC. The urinary excretion values of these three metabolites after the simultaneous infusion of gludopa and glu-5-HTP were not significantly different from those observed after the infusion of gludopa alone (Tables 1-3 ). The administration of glu-5-HTP alone did not affect the urinary excretion of L-dopa, dopamine and DOPAC when compared with infusion of placebo. Table 4 shows the urinary excretion rates of 5-HT, L-~-HTP and 5-HIAA on the four experimental days. Urinary 5-HT excretion rate increased markedly from 0.4 nmol/min during the run-in period to a peak value of 291nmol/min at the end of glu-5-HTP infusion, whereas it remained fairly constant on the placebo day. The 3-6h cumulative 5-HT excretion after glu-5-HTP was about 430-fold higher than that after placebo infusion (Table 2 ) and this increment in urinary 5-HT excretion was equivalent to 15 f 2% of the infused molar dose of glu-5-HTP ( Table 5 ). There were also marked increases in the urinary excretion rates of L-~-HTP and 5-HIAA after the administration of glu-5-HTP. During the 3-6h period, 56+5% of the dose of glu-5-HTP infused was recovered in the urine as the sum of L-5-HTP, 5-HT and 5-HIAA. The urinary excretion rates of these three metabolites after the simultaneous infusion of gludopa and glu-5-HTP were not significantly different from those measured after infusion of glu-5-HTP alone (Tables 2, 4, 5). The infusion of gludopa alone produced an unexpected increase in the urinary excretion rate of 5-HT from an average baseline value of 0.5 nmol/min to a mean peak value of 4.3nmol/min. The 3-6h cumulative 5-HT excretion was 481 f 125 nmol after gludopa infusion and 81 f 23 nmol after placebo (mean difference: 400; 99% CIdiff: 242 to 558nmol; Pc0.001). The increase in 5-HT excretion induced by gludopa occurred in every subject. 
RESULTS

Urinary excretion of dopamine, Ldopa and DOPAC
Urinary excretion of EHT, L-EHTP and EHlAA
(1.4) 
Urinary excretion of sodium and water
The urinary sodium excretion, estimated from the 24 h urine collection, was in excess of 200 mmol/day for every subject [mean 264 (SD 68) mmol/day], consistent with a high salt intake. Gludopa significantly increased urinary sodium excretion ( P < 0.05) and FEN, (P < 0.02) when compared with infusion of placebo only (Fig. 1) . The changes in the 3-6 h cumulative sodium excretion values, relative to the baseline excretion rates, after infusion of placebo and gludopa were +2.3+ 15.6 and 65.2 mmol; P < 0.05). The mean urinary sodium excretion rates after the combined infusion of gludopa and glu-5-HTP were greater than those measured on placebo day, but the differences were not statistically significant (mean difference in cumulative sodium excretion: +24.0; 99% CIdiff: -4.6 to 52.6mmol). The changes in FEN, values after the combined infusion of gludopa and glu-5-HTP7 however, nearly reached statistical significance (P = 0.06) when compared with placebo infusion. The urinary sodium excretion rate and FEN, values after the concomitant infusion of gludopa and glu-5-HTP were not significantly different from those observed on gludopa infusion day (mean difference in the cumulative sodium excretion: -9.8; 99% CIdifC -39.9 to 20.4mmol). There was a trend towards an increase in urine flow rate after infusion of gludopa and a reduction in urine output after glu-5-HTP7 but these changes were not statistically significant when compared with those observed after infusion of placebo (T. C. Li Kam Wa, S. Freestone, R. R. Samson, N. R. Johnston and M. R. Lee, unpublished work). There was, however, a significant treatment x time interaction (P<O.O2) when the urine flow rate values after gludopa infusion were compared with those after glu-5-HTP infusion. There were no significant differences in the changes in cumulative urine output between the four study days [F(3,21) =0.97, P=O.4]. ERPF when compared with placebo infusion (P<O.O2; Fig. 2 ). The changes in ERPF after infusion of gludopa alone or after the combined infusion of gludopa and glu-5-HTP were not significantly different from those measured on placebo day. There were no significant differences in GFR or FF values between the four experimental days. There was a trend towards a decrease in GFR after infusion of glu-SHTP, but this reduction just failed to reach statistical significance when compared with placebo (P=0.08). As a result, the FF values after infusion of glu-5-HTP, in contrast to the ERPF values, were not significantly different from those observed after infusion of placebo only.
ERPF, GFR and FF
Glu-5-HTP produced a significant reduction in
DISCUSSION
Administration of gludopa was associated with marked increases in the urinary excretion of L-dopa, dopamine and DOPAC together with a rise in the urinary excretion of sodium, in agreement with published studies from our group [17, [21] [22] [23] [24] . A diuresis as well as a small increase in both ERPF and GFR have also been reported [21-241. In the present study, we were unable to demonstrate significant differences in urinary volumes and renal haemodynamics between gludopa and placebo infusion days, but the highest mean urinary flow rates were observed on the day the subjects received gludopa. The absence of an effect on renal haemodynamics may be partly due to the shorter duration of gludopa infusion employed, and hence the total dose of gludopa administered. In addition, our subjects were volume expanded and salt-replete, and the renal vasculature may exhibit background vasodilatation in such conditions, making it more difficult to demonstrate an additional vasodilator effect of dopamine.
The increased dopamine excretion after gludopa can be observed in the isolated perfused rat kidney [25] and occurs with minimal increases in circulating plasma dopamine levels when given in low doses in the rat [26] and in man [21, 271 , indicating direct intrarenal synthesis of dopamine and its subsequent excretion. The enhanced sodium excretion induced by gludopa is mainly a result of the inhibitory effect of dopamine (probably formed within the cells of the proximal tubules) upon the tubular reabsorption of this cation, since it can occur in man without detectable changes in renal haemodynamics [ 17, 231. This is supported by observations in the isolated perfused rat kidney that dopamine-induced natriuresis and diuresis could persist even when renal blood flow, GFR and perfusion pressure were kept constant [28] . In the present study, the idcreased FEN, and the absence of significant changes in renal haemodynamics after infusion of gludopa would also be in agreement with a tubular site (or sites) for the action of dopamine. The latter may act by inhibiting Na+-K+-ATPase at the basolateral membrane as well as Na+-H+ antiport activity at the brush border membrane in the proximal tubular segments C2, 291.
Glu-5-HTP produced marked increases in the urinary excretion of L-~-HTP, 5-HT and 5-HIAA. We have demonstrated these changes in other studies and have shown that the marked increase in urine 5-HT excretion occurred without concomitant increases in circulating 5-HT levels measured in platelet-rich plasma, consistent with the proposition that it was primarily due to the intrarenal synthesis of 5-HT [5, 20, 30, 311. Glu-5-HTP was also shown to reduce the urinary excretion of sodium and FEN, without affecting ERPF or GFR in the previous studies, and this sodium-retaining effect was dependent on the conversion of glu-5-HTP to 5-HT. In the present study, glu-5-HTP produced a significant reduction in ERPF and a trend towards a fall in GFR. These effects may be partly due to the slightly higher dose of glu-5-HTP employed in this study (20 compared with 16.6pgmin-' kg-I). The absence of a significant antinatriuretic effect after glu-5-HTP in the present investigation is also at variance with our previous results [5, 20, 301. However, the mean urinary sodium excretion rates after glu-5-HTP were lower than those observed on the placebo day and a type 2 error may account for the failure to observe a significant effect. In addition, the sodium excretion values during the baseline periods were much higher than in previous studies [5, 20, 301 as a result of salt loading, and the antinatriuretic action of 5-HT may be less easily demonstrable in this state. The high sodium intake may overwhelm the tubular response to a relatively weak modulator of renal sodium excretion such as 5-HT. It is also possible that increased salt intake may have led to a downregulation of the tubular 5-HT receptors in an attempt to facilitate renal sodium excretion.
Dopamine is produced from gludopa after the sequential enzymic actions of y-GT and LAAD [14, 17, 251 , and a similar mechanism probably accounts for the release of 5-HT from glu-5-HTP. The activity of y-GT in mammalian tissues is at its highest in the kidney [l5, 161. This membranebound glycoprotein is heavily concentrated on the brush border of the proximal tubular cells but it is also found at the antiluminal border of these tubules at a lower concentration [32] . At these sites, the enzyme is orientated in the membranes so as to react with substrates present in the extracellular milieu [33] . y-GT will cleave the y-glutamyl moieties of gludopa and glu-5-HTP releasing the free amino acid precursors, L-dopa and L-5-HTP respectively, in relatively high quantities on both sides of the proximal tubular cells for subsequent decarboxylation. The enzyme has a tremendous capacity to metabolize y-glutamyl compounds, as shown by the very low recovery of unmetabolized gludopa in the urine (~1 % ) after its intravenous infusion in man [27, In the present study, the urinary excretion values of L-dopa, dopamine and DOPAC after the simultaneous infusion of equimolar amounts of gludopa and glu-5-HTP were not significantly different from those observed after the infusion of gludopa only. Similarly, the urinary levels of L-~-HTP; 5-HT and 5-HIAA after the co-infusion were similar to those measured after the administration of glu-5-HTP alone. These observations would suggest that, under the conditions of our study, there was no competition between the two compounds for the renal enzymes or transporters. These systems, however, may not be readily susceptible to saturation at the substrate load that we supplied and this may explain the failure to demonstrate an inhibition of synthesis of either amine. That enzyme saturation may not occur at the doses employed in this study is supported by a previous report which demonstrated that the mean percentage conversion of administered gludopa to urine free dopamine did not fall when the dose of gludopa was increased from 12.5 to 100pgmin-'kg-' [21] . An alternative explanation is that the prodrugs are metabolized in different compartments within the renal tubular cells. The amount of dopamine produced, as measured in the urine, was approximately 75% greater than the quantity of urinary 5-HT generated after infusion of equimolar amounts of the two glutamyl compounds. This suggests that LAAD in the kidney preferentially decarboxylates L-dopa and is consistent with previous studies in uivo and in vitro in the rat demonstrating that L-dopa is the preferred substrate for renal LAAD [42, 431 . Itskovitz et al. [6] also reported that comparatively more dopamine than 5-HT was excreted when L-5-HTP and L-dopa were infused together into the renal artery of the rat. In addition, there was no evidence from the study by Itskovitz et al. [6] that L-dopa acted as a competitive inhibitor and diminished the renal synthesis of 5-HT during the combined infusion of L-5-HTP and L-dopa.
There was an unexpected rise in urinary 5-HT excretion after infusion of gludopa. We did not, however, observe an effect on 5-HIAA excretion, but this may be due to the failure of our spectrophotometric assay to detect low concentrations of 5-HIAA. In contrast, glu-5-HTP infusion had no effect on dopamine excretion, consistent with a similar finding in a previous study [S]. The reason for the increased 5-HT excretion is unclear. It may result from displacement of endogenous renal 5-HT by dopamine derived from gludopa analogous to the situation in the brain of the rat where administration of L-dopa leads to cerebral accumulation of dopamine, together with a reduction of cerebral 5-HT, probably caused by a release or displacement (or both) of endogenous 5-HT from its storage sites by the large excess of dopamine [44, 451. The increased 5-HT excretion after gludopa may also be related to the natriuresis induced by gludopa, perhaps as a renal response to the need to conserve sodium. It is also possible that it is merely a flowdependent phenomenon and represents a 'wash-out' of preformed 5-HT from the tubular lumen related to the increased urinary flow rate induced by gludopa. However, although the urinary flow rate values tended to be higher on gludopa infusion day in the present study, they were not significantly different from those measured after infusion of placebo only.
In the present study, the overall pharmacological effect of infusing gludopa and glu-5-HTP simultaneously was towards increased sodium excretion. This may be due to the greater amount of dopamine than 5-HT synthesized intrarenally after infusion of equimolar amounts of the two glutamyl derivatives under the conditions of this study. It is of interest in this respect that studies have demonstrated that the rate of uptake of L-dopa and formation of dopamine by renal cortical slices varied with the concentration of sodium in the incubation medium [46, 471, and that urinary excretion rates of L-dopa and dopamine after infusion of L-dopa were observed to be higher after dietary salt loading in man [ll]. In addition, the natriuretic effect of dopamine has been shown to be more evident with salt loading or extracellular fluid volume expansion [48, 491. Whether this is as a result of a volume-induced u p regulation of dopamine receptors or an increased efficiency of coupling to signal transduction is unclear. There may also be down-regulation of the 5-HT receptors, as we suggested earlier, since we were unable to demonstrate the sodium-retaining effect of glu-5-HTP when infused alone, in contrast to our previous studies [5, 20, 301. The present study should be repeated in man under conditions of sodium deprivation to see if the sodium intake did have an effect on the sensitivity to the antinatriuretic action of 5-HT and whether there would be any alteration in the relative amounts of dopamine and 5-HT excreted.
In conclusion, our investigation in salt-replete (or salt-loaded) subjects has demonstrated that dopamine was the preferred amine to be synthesized. The overall effect on sodium excretion was to produce a natriuresis when equimolar doses of gludopa and glu-5-HTP were administered simultaneously. It is not clear whether similar effects would be observed under physiological conditions. It is of interest, however, to note that reciprocal changes in urinary excretion of endogenous dopamine and 5-HT have been shown to occur in man when salt intake is altered [7-121.
